Preliminary data from Biomica's Phase 1 study
of BMC128 will be showcased at the conference
REHOVOT, Israel, April 16,
2024 /PRNewswire/ -- Biomica Ltd., a
clinical-stage biopharmaceutical company developing innovative
microbiome-based therapeutics and a subsidiary of Evogene
Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that it will
present preliminary data from its Phase 1 study of BMC128,
in combination with immune checkpoint inhibitor (ICI)
immunotherapy, in refractory patients with either non-small cell
lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC), who
previously progressed on immunotherapy, at the American
Society of Clinical Oncology (ASCO) Annual Meeting. The
conference will take place at McCormick Place in Chicago, Illinois, and will also be available
virtually from May 31 to June 4,
2024.
Presentation Details:
Title: Preliminary results from a First-in-Human
(FIH), open-label Phase 1 study with BMC128, a rationally designed
live bacterial consortium, in combination with nivolumab.
Session Type: Poster Session
Abstract Number: 8631
Date and Time: June 3, 2024, 1:30 PM –
4:30 PM (CDT)
Dr. Elran Haber, CEO of Biomica, stated: "We look forward
to presenting our preliminary data at ASCO, and to provide initial
safety and efficacy results from our ongoing Phase 1 POC trial
evaluating BMC-128 in combination with nivolumab in refractory
patients. These results mark significant progress, laying the
groundwork for the next phase in our clinical development
process".
Additional information about the trial, can be found at:
https://clinicaltrials.gov (ClinicalTrials.gov
Identifier: NCT05354102).
About BMC128:
BMC128 is a rationally designed
microbial consortium identified and selected through a detailed
functional microbiome analysis using PRISM, a proprietary
high-resolution microbiome analysis platform powered by Evogene's
MicroBoost AI tech-engine.
Developed as a Live Bacterial Product (LBP), BMC128 is an LBP
consortium comprised of four unique bacterial strains, natural
inhabitants of the human intestinal tract, that harbor specific
functional capabilities with the potential to enhance immunological
therapeutic responses and facilitate anti-tumor immune activity
through multiple biological processes.
Rationally-designed consortia are multi-strain products designed to
restore diversity and specific functionality to a host's microbial
community with individually selected, cultured bacteria.
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing PRISM system, a
proprietary computational platform powered by Evogene's
MicroBoost AI tech-engine licensed from Evogene. Biomica
aims to identify and characterize disease-related microbiome
entities and to develop novel therapeutics based on these
understandings. The company is focused on the development of
therapies for antibiotic resistant bacteria, immuno-oncology, and
microbiome-related gastrointestinal (GI) disorders. Biomica is a
subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN).
For more information, please visit www.biomicamed.com
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a computational biology
company aiming to revolutionize the development of
life-science-based products by utilizing cutting-edge technologies
to increase the probability of success while reducing development
time and cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass AI, and GeneRator AI –
leveraging Big Data and Artificial Intelligence and incorporating
deep multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of products
based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus
and castor varieties for the biofuel and other industries, by
Casterra.
For more information, please visit www.evogene.com.
Forward-Looking Statements:
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "hopes" "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates" or words of similar meaning. For example, Evogene
and its subsidiaries are using forward-looking statement in this
press release when they discusses safety and efficacy results
from Biomica's Phase 1 POC trial evaluating BMC-128 in combination
with nivolumab in refractory patients, and the progress to the
next phase in its clinical development process. Such statements
are based on current expectations, estimates, projections and
assumptions, describe opinions about future events, involve certain
risks and uncertainties which are difficult to predict and are not
guarantees of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, the current war between Israel and Hamas and any worsening of the
situation in Israel such as
further mobilizations or escalation in the northern border of
Israel and those risk
factors contained in Evogene's reports filed with the applicable
securities authority. In addition, Evogene and its subsidiaries
rely, and expect to continue to rely, on third parties to conduct
certain activities, such as their field-trials and pre-clinical
studies, and if these third parties do not successfully carry out
their contractual duties, comply with regulatory requirements or
meet expected deadlines, Evogene and its subsidiaries may
experience significant delays in the conduct of their activities.
Evogene and its subsidiaries disclaim any obligation or commitment
to update these forward-looking statements to reflect future events
or developments or changes in expectations, estimates, projections
and assumptions.
Contact
Rachel Pomerantz
Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/1974949/Biomica.jpg
View original
content:https://www.prnewswire.com/news-releases/biomica-to-present-at-the-american-society-of-clinical-oncology-asco-2024-annual-meeting-302117932.html
SOURCE Biomica Ltd.